View Document Preview and Link Document Date: 2013-09-17 12:37:08 Open Document File Size: 83,00 KB Share Result on Facebook
City Duesseldorf / New York / Paris / Leverkusen / / Company The Bayer Group / Genzyme Corporation / Sanofi Company / EMD Serono Inc. / Bayer AG / / Continent Europe / / Country Germany / Chile / France / United States / Australia / Argentina / South Korea / / Currency EUR / / Event FDA Phase / Company Listing Change / / IndustryTerm high-tech materials / Multiple Sclerosis Treatment / pharmaceutical / healthcare / therapeutic solutions / consumer healthcare / diabetes solutions / / MedicalCondition MS disease / rare and debilitating diseases / rare diseases / headache / inflammatory process / thyroid disease / leukopenia / nausea / thrombocytopenia / hyperthyroidism / fatigue / multiple sclerosis / glomerulonephritis / lymphopenia / MS / pruritus / infections / company’s investigational multiple sclerosis / flushing / disease / hypothyroidism / diabetes / fever / active disease / relapsing remitting multiplE scleRosis / Virus (HIV) infection / urticaria / remitting multiple sclerosis / rash / / MedicalTreatment intravenous infusion / oral therapy / / Organization European Commission / FDA / European Union / / Person David Meeker / Hans-Peter Hartung / John Golding / / Position President / Professor and Chairman of the Department / integrated global healthcare leader / CEO and President / President of the European Multiple Sclerosis Platform / / Product LemtradaTM / Rebif / Sclerosis Treatment Aubagio® (teriflunomide) / TEriflunomide Multiple Sclerosis Oral / Lemtrada™ / / ProvinceOrState Mississippi / / Technology therapeutic solutions / / URL http / SocialTag 
PRESS RELEASE European Commission Approves Genzyme’s Multiple Sclerosis